Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy, Vikas Gupta, J. Dipersio, J. Catalano, M. Deininger, Carole Miller, R. Silver, M. Talpaz, E. Winton, J. Harvey, M. Arcasoy, E. Hexner, R. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson‐Viitanen, I. Koumenis, William Sun, V. Sandor, H. Kantarjian (2012)
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.The New England journal of medicine, 366 9
C. Harrison, A. Vannucchi, J. Kiladjian, H. Al-Ali, H. Gisslinger, L. Knoops, F. Cervantes, Mark Jones, K. Sun, M. Mcquitty, V. Stalbovskaya, Prashanth Gopalakrishna, T. Barbui (2016)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia, 30
F. Cervantes, B. Dupriez, Arturo Pereira, F. Passamonti, J. Reilly, E. Morra, A. Vannucchi, R. Mesa, J. Demory, G. Barosi, E. Rumi, A. Tefferi (2008)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.Blood, 113 13
A. Tefferi, F. Cervantes, R. Mesa, F. Passamonti, S. Verstovsek, A. Vannucchi, J. Gotlib, B. Dupriez, A. Pardanani, C. Harrison, R. Hoffman, H. Gisslinger, N. Kröger, J. Thiele, T. Barbui, G. Barosi (2013)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.Blood, 122 8
C. Cerchione, I. Peluso, D. Nappi, A. Pareto, M. Picardi, V. Martinelli, F. Pane (2017)
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosisAnnals of Hematology, 96
H. Al-Ali, M. Griesshammer, P. Coutre, C. Waller, A. Liberati, P. Schafhausen, R. Tavares, P. Giraldo, L. Foltz, P. Raanani, Vikas Gupta, B. Tannir, J. Ronco, Jagannath Ghosh, B. Martino, A. Vannucchi (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialHaematologica, 101
C. Harrison, J. Kiladjian, H. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. Mcquitty, D. Hunter, R. Levy, L. Knoops, F. Cervantes, A. Vannucchi, T. Barbui, G. Barosi (2012)
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.The New England journal of medicine, 366 9
M. Marchetti, G. Barosi, M. Griesshammer, R. Hehlmann, M. Monia, Barosi Giovanni, Cervantes Francisco, Birgegård Gunnar, Griesshammer Martin, Harris Claire, H. Rüdiger, Kiladjian Jean-Jacques, Kroger Nicolaus, McMullin Mary, Frances, Passamonti Francesco, Vannucchi Alessandro, Barbui Tiziano, DH PhDEmatologia, Soc Oncologia (2017)
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendationsLeukemia, 31
R. Emanuel, A. Dueck, H. Geyer, J. Kiladjian, S. Slot, S. Zweegman, P. Boekhorst, S. Commandeur, H. Schouten, F. Sackmann, A. Fuentes, D. Hernández‐Maraver, H. Pahl, M. Griesshammer, F. Stegelmann, K. Doehner, T. Lehmann, Karin Bonatz, A. Reiter, F. Boyer, G. Étienne, J. Ianotto, D. Ranta, L. Roy, J. Cahn, C. Harrison, D. Radia, P. Muxí, N. Maldonado, C. Besses, F. Cervantes, P. Johansson, T. Barbui, G. Barosi, A. Vannucchi, F. Passamonti, B. Andreasson, M. Ferrari, A. Rambaldi, J. Samuelsson, G. Birgegard, A. Tefferi, R. Mesa (2012)
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 33
T. Barbui, A. Tefferi, A. Vannucchi, F. Passamonti, R. Silver, R. Hoffman, S. Verstovsek, R. Mesa, J. Kiladjian, R. Hehlmann, A. Reiter, F. Cervantes, C. Harrison, M. Mullin, H. Hasselbalch, S. Koschmieder, M. Marchetti, A. Bacigalupo, G. Finazzi, N. Kroeger, M. Griesshammer, G. Birgegard, G. Barosi (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetLeukemia, 32
D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz, M. Beau, C. Bloomfield, M. Cazzola, J. Vardiman (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood, 127 20
G. Caocci, S. Ghiani, C. Mocci, G. Nasa (2018)
Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with MyelofibrosisActa Haematologica, 139
N. Polverelli, L. Catani, N. Vianelli, M. Baccarani, Michele Cavo, F. Palandri (2015)
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptomsAnnals of Hematology, 94
F. Passamonti, F. Cervantes, A. Vannucchi, E. Morra, E. Rumi, Arturo Pereira, P. Guglielmelli, E. Pungolino, M. Caramella, M. Maffioli, C. Pascutto, M. Lazzarino, M. Cazzola, A. Tefferi (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).Blood, 115 9
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.Blood, 114 5
J. Kiladjian (2015)
Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
F. Palandri, G. Palumbo, M. Bonifacio, M. Tiribelli, G. Benevolo, B. Martino, E. Abruzzese, M. D’adda, N. Polverelli, M. Bergamaschi, A. Tieghi, F. Cavazzini, A. Ibatici, M. Crugnola, C. Bosi, R. Latagliata, A. Veroli, L. Scaffidi, F. Marchi, E. Cerqui, B. Anaclerico, G. Matteis, Marco Spinsanti, E. Sabattini, L. Catani, F. Aversa, F. Raimondo, U. Vitolo, R. Lemoli, R. Fanin, F. Merli, D. Russo, A. Cuneo, M. Reggiani, M. Cavo, N. Vianelli, M. Breccia (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisOncotarget, 8
A. Martínez‐Trillos, A. Gaya, M. Maffioli, E. Arellano-Rodrigo, X. Calvo, M. Díaz-Beyá, F. Cervantes (2010)
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patientsAnnals of Hematology, 89
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomeg- aly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p =0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed. . . . Keywords Myelofibrosis Ruxolitinib Hydroxyurea Efficacy Introduction by hyperleukocytosis and thrombocytosis [2]. Ruxolitinib (JAKAVI, Novartis; JAKAFI, Incyte Corporation) is the first- Myelofibrosis (MF) is the most aggressive among Philadelphia- in-class JAK1/2 inhibitor that has demonstrated efficacy in reduc- negative chronic myeloproliferative neoplasms (MPN) and
Annals of Hematology – Springer Journals
Published: Jun 14, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.